Observational studies versus randomized controlled trials: avenues to causal inference in nephrology
- PMID: 22364796
- PMCID: PMC3293157
- DOI: 10.1053/j.ackd.2011.09.004
Observational studies versus randomized controlled trials: avenues to causal inference in nephrology
Abstract
A common frustration for practicing Nephrologists is the adage that the lack of randomized controlled trials (RCTs) does not allow us to establish causality, but merely associations. The field of nephrology, like many other disciplines, has been suffering from a lack of RCTs. The view that without RCTs, there is no reliable evidence has hampered our ability to ascertain the best course of action for our patients. However, many clinically important questions in medicine and public health, such as the association of smoking and lung cancer, are not amenable to RCTs owing to ethical or other considerations. Whereas RCTs unquestionably hold many advantages over observational studies, it should be recognized that they also have many flaws that render them fallible under certain circumstances. We provide a description of the various pros and cons of RCTs and of observational studies using examples from the nephrology literature, and argue that it is simplistic to rank them solely based on preconceived notions about the superiority of one over the other. We also discuss methods whereby observational studies can become acceptable tools for causal inferences. Such approaches are especially important in a field like nephrology where there are myriads of potential interventions based on complex pathophysiologic states, but where properly designed and conducted RCTs for all of these will probably never materialize.
Published by Elsevier Inc.
Figures
References
-
- KDIGO clinical practice guideline for the diagnosis, evaluation prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Kidney Int Suppl. 2009;76 (113):S1–S130. - PubMed
-
- Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–590. - PubMed
-
- Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084. - PubMed
-
- Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeew D, Eckardt KU, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032. - PubMed
-
- Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous